Assembly Biosciences Revenue vs. Current Valuation
| ASMB Stock | USD 26.22 0.83 3.27% |
Total Revenue | First Reported 2008-12-31 | Previous Quarter 9.6 M | Current Value 10.8 M | Quarterly Volatility 2 B |
For Assembly Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Assembly Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Assembly Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Assembly Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Assembly Biosciences over time as well as its relative position and ranking within its peers.
Check out Trending Equities. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Assembly Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.60) | Revenue Per Share | Quarterly Revenue Growth 0.576 | Return On Assets | Return On Equity |
Assembly Biosciences's market price often diverges from its book value, the accounting figure shown on Assembly's balance sheet. Smart investors calculate Assembly Biosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Assembly Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Assembly Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Assembly Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Assembly Biosciences Current Valuation vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Assembly Biosciences's current stock value. Our valuation model uses many indicators to compare Assembly Biosciences value to that of its competitors to determine the firm's financial worth. Assembly Biosciences is rated third in revenue category among its peers. It also is rated third in current valuation category among its peers reporting about 6.94 of Current Valuation per Revenue. At present, Assembly Biosciences' Total Revenue is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Assembly Biosciences' earnings, one of the primary drivers of an investment's value.Assembly Revenue vs. Competition
Assembly Biosciences is rated third in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 270.98 Million. Assembly Biosciences retains roughly 28.52 Million in revenue claiming about 11% of equities under Health Care industry.
Assembly Current Valuation vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Assembly Biosciences |
| = | 28.52 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Assembly Biosciences |
| = | 198.05 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Assembly Current Valuation vs Competition
Assembly Biosciences is rated third in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 1.55 Billion. Assembly Biosciences retains roughly 198.05 Million in current valuation claiming about 13% of equities under Health Care industry.
Assembly Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Assembly Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Assembly Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Assembly Biosciences' change in net profit over the period of time. It can combine multiple indicators of Assembly Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -189.9 K | -199.4 K | |
| Operating Income | -40.9 M | -42.9 M | |
| Net Loss | -36.2 M | -38 M | |
| Income Tax Expense | 379.5 K | 398.5 K | |
| Total Other Income Expense Net | 6.4 M | 6.7 M | |
| Income Before Tax | -45.8 M | -48.1 M | |
| Net Loss | -36.2 M | -38 M | |
| Non Operating Income Net Other | 1.2 M | 1.3 M | |
| Net Loss | -83.8 M | -88 M | |
| Net Interest Income | 6.4 M | 6.7 M | |
| Interest Income | 6.4 M | 6.7 M | |
| Change To Netincome | 11.6 M | 15.8 M | |
| Net Loss | (6.02) | (6.32) | |
| Income Quality | 1.15 | 1.20 | |
| Net Income Per E B T | 0.91 | 0.61 |
Assembly Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Assembly Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Assembly Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Assembly Biosciences' important profitability drivers and their relationship over time.
Assembly Biosciences Earnings Estimation Breakdown
The calculation of Assembly Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Assembly Biosciences is estimated to be -0.9275 with the future projection ranging from a low of -1.0775 to a high of -0.825. Please be aware that this consensus of annual earnings estimates for Assembly Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.08 Lowest | Expected EPS | -0.82 Highest |
Assembly Biosciences Earnings Projection Consensus
Suppose the current estimates of Assembly Biosciences' value are higher than the current market price of the Assembly Biosciences stock. In this case, investors may conclude that Assembly Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Assembly Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 4 | 67.48% | -0.72 | -0.9275 | -4.6 |
Assembly Biosciences Earnings per Share Projection vs Actual
Actual Earning per Share of Assembly Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Assembly Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Assembly Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Assembly Biosciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Assembly Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Assembly Biosciences should always be considered in relation to other companies to make a more educated investment decision.Assembly Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Assembly Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-10 | 2025-09-30 | -1.57 | -0.72 | 0.85 | 54 | ||
2025-08-06 | 2025-06-30 | -1.61 | -1.33 | 0.28 | 17 | ||
2025-05-06 | 2025-03-31 | -1.6 | -1.17 | 0.43 | 26 | ||
2025-03-26 | 2024-12-31 | -1.75 | -1.57 | 0.18 | 10 | ||
2024-11-06 | 2024-09-30 | -2.02 | -1.51 | 0.51 | 25 | ||
2024-08-08 | 2024-06-30 | -2.23 | -2.05 | 0.18 | 8 | ||
2024-05-08 | 2024-03-31 | -3.23 | -1.66 | 1.57 | 48 | ||
2024-01-31 | 2023-12-31 | -2.88 | -2.15 | 0.73 | 25 | ||
2023-11-08 | 2023-09-30 | -0.23 | -0.27 | -0.04 | 17 | ||
2023-08-09 | 2023-06-30 | -0.29 | -0.32 | -0.03 | 10 | ||
2023-05-04 | 2023-03-31 | -0.35 | -0.37 | -0.02 | 5 | ||
2023-03-22 | 2022-12-31 | -0.45 | -0.46 | -0.01 | 2 | ||
2022-11-08 | 2022-09-30 | -0.47 | -0.48 | -0.01 | 2 | ||
2022-08-09 | 2022-06-30 | -0.47 | -0.51 | -0.04 | 8 | ||
2022-05-12 | 2022-03-31 | -0.47 | -0.48 | -0.01 | 2 | ||
2022-03-10 | 2021-12-31 | -0.48 | -0.38 | 0.1 | 20 | ||
2021-11-04 | 2021-09-30 | -0.56 | -0.41 | 0.15 | 26 | ||
2021-08-05 | 2021-06-30 | -0.66 | -0.55 | 0.11 | 16 | ||
2021-05-06 | 2021-03-31 | -0.79 | -0.69 | 0.1 | 12 | ||
2021-02-25 | 2020-12-31 | -0.9 | -0.96 | -0.06 | 6 | ||
2020-11-05 | 2020-09-30 | -0.75 | -0.09 | 0.66 | 88 | ||
2020-08-05 | 2020-06-30 | -0.03 | 0.19 | 0.22 | 733 | ||
2020-05-07 | 2020-03-31 | -0.98 | -0.76 | 0.22 | 22 | ||
2020-03-04 | 2019-12-31 | -1.01 | -0.99 | 0.02 | 1 | ||
2019-11-07 | 2019-09-30 | -0.93 | -0.96 | -0.03 | 3 | ||
2019-08-05 | 2019-06-30 | -1.15 | -0.72 | 0.43 | 37 | ||
2019-05-09 | 2019-03-31 | -1.04 | -1.05 | -0.01 | 0 | ||
2019-02-28 | 2018-12-31 | -0.9 | -1.03 | -0.13 | 14 | ||
2018-11-08 | 2018-09-30 | -1.03 | -0.87 | 0.16 | 15 | ||
2018-08-08 | 2018-06-30 | -0.86 | -1.3 | -0.44 | 51 | ||
2018-05-07 | 2018-03-31 | -0.76 | -0.8 | -0.04 | 5 | ||
2018-03-08 | 2017-12-31 | -0.79 | -0.36 | 0.43 | 54 | ||
2017-11-01 | 2017-09-30 | -0.88 | -0.71 | 0.17 | 19 | ||
2017-08-09 | 2017-06-30 | -0.79 | -0.78 | 0.01 | 1 | ||
2017-05-08 | 2017-03-31 | -0.03 | -0.81 | -0.78 | 2600 | ||
2017-03-02 | 2016-12-31 | -0.67 | -0.67 | 0.0 | 0 | ||
2016-11-09 | 2016-09-30 | -0.67 | -0.67 | 0.0 | 0 | ||
2015-03-12 | 2014-12-31 | -0.57 | -0.38 | 0.19 | 33 | ||
2014-11-17 | 2014-09-30 | -0.48 | -1.33 | -0.85 | 177 | ||
2014-08-14 | 2014-06-30 | -0.65 | -0.52 | 0.13 | 20 | ||
2014-05-14 | 2014-03-31 | -0.7 | -0.9 | -0.2 | 28 | ||
2014-03-17 | 2013-12-31 | -1.4 | -0.29 | 1.11 | 79 | ||
2013-11-12 | 2013-09-30 | -1.3 | -1.25 | 0.05 | 3 | ||
2013-08-09 | 2013-06-30 | -1 | -1.2 | -0.2 | 20 | ||
2013-05-10 | 2013-03-31 | -1.1 | -1.1 | 0.0 | 0 | ||
2013-03-18 | 2012-12-31 | -1.54 | -1.4 | 0.14 | 9 | ||
2012-11-13 | 2012-09-30 | -1.94 | -2.05 | -0.11 | 5 | ||
2012-08-09 | 2012-06-30 | -2.89 | -2.95 | -0.06 | 2 | ||
2012-05-07 | 2012-03-31 | -2.51 | -3.3 | -0.79 | 31 | ||
2012-03-14 | 2011-12-31 | -5.42 | -8.9 | -3.48 | 64 | ||
2011-11-14 | 2011-09-30 | -2.5 | -2.5 | 0.0 | 0 | ||
2011-08-15 | 2011-06-30 | -2.55 | -4.85 | -2.3 | 90 | ||
2011-05-16 | 2011-03-31 | -0.87 | -1.9 | -1.03 | 118 |
Use Assembly Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Assembly Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Assembly Biosciences will appreciate offsetting losses from the drop in the long position's value.Assembly Biosciences Pair Trading
Assembly Biosciences Pair Trading Analysis
The ability to find closely correlated positions to Assembly Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Assembly Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Assembly Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Assembly Biosciences to buy it.
The correlation of Assembly Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Assembly Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Assembly Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Assembly Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Assembly Biosciences position
In addition to having Assembly Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tips ETFs Thematic Idea Now
Tips ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Tips ETFs theme has 35 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tips ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
To fully project Assembly Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Assembly Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Assembly Biosciences' income statement, its balance sheet, and the statement of cash flows.